Tsukita Yoko 突田容子

Researcher Number	50822566
Other IDs
Affiliation (Current)	2025: 東北大学, 大学病院, 助教
Affiliation (based on the past Project Information) *help	2020 – 2023: 東北大学, 大学病院, 助教 2018 – 2019: 東北大学, 大学病院, 医員
Review Section/Research Field	Principal Investigator Basic Section 53030:Respiratory medicine-related / 0901:Oncology and related fields
Keywords	Principal Investigator 肺癌 / 免疫療法 / 非小細胞肺癌 / NK細胞 / CARS2

進行期非小細胞肺癌の免疫併用療法におけるNK細胞の役割の解明Principal Investigator
- Principal Investigator
  
  突田容子
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Tohoku University
Analysis of immune response induced by radiotherapy in non-small cell lung cancerPrincipal Investigator
- Principal Investigator
  
  Tsukita Yoko
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Tohoku University
The role of reactive sulfur species and cysteinyl-tRNA synthetase2 in lung cancerPrincipal Investigator
- Principal Investigator
  
  Tsukita Yoko
- Project Period (FY)
  2018 – 2019
- Research Category
  
  Grant-in-Aid for Research Activity Start-up
- Review Section
  
  0901:Oncology and related fields
- Research Institution
  Tohoku University

All 2024 2023 2022 2021 2020 2019 2018

All Journal Article Presentation

[Journal Article] Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70?years or older (‘MONEY’ trial)2024
- Author(s)
  Tsukita Yoko、Taguri Masataka、Goto Yasushi、Hosomi Yukio、Mizutani Tomonori、Watanabe Kageaki、Yoh Kiyotaka、Takahashi Satoshi、Kubota Kaoru、Kunitoh Hideo
- Journal Title
  
  Japanese Journal of Clinical Oncology
  
  Volume: - Issue: 6 Pages: 730-734
- DOI
  10.1093/jjco/hyae032
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K15180
[Journal Article] Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non?Small Cell Lung Cancer2024
- Author(s)
  Tsukita Yoko、Tozuka Takehiro、Kushiro Kohei、Hosokawa Shinobu、Sumi Toshiyuki、Uematsu Mao、Honjo Osamu、Yamaguchi Ou、Asao Tetsuhiko、Sugisaka Jun、Saito Go、Shiihara Jun、Morita Ryo、Katakura Seigo、Yasuda Takehiro、Hisakane Kakeru、Miyauchi Eisaku、Morita Satoshi、Kobayashi Kunihiko、Asahina Hajime
- Journal Title
  
  JAMA Oncology
  
  Volume: - Issue: 4 Pages: 439-439
- DOI
  10.1001/jamaoncol.2023.6277
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K15180
[Journal Article] First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.2022
- Author(s)
  Yoko Tsukita, Akira Inoue
- Journal Title
  
  Japanese Journal of Clinical Oncology
  
  Volume: 52 Issue: 5 Pages: 405-410
- DOI
  10.1093/jjco/hyac012
- Data Source
  KAKENHI-PROJECT-20K17207
[Journal Article] Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.2021
- Author(s)
  Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, Tanaka S, Uchida J, Usui K, Toyoda T, Tamiya M, Morimoto M, Oya Y, Kodaira T, Miyauchi E, Jingu K, Sugiura H.
- Journal Title
  
  Radiother Oncol.
  
  Volume: 160 Pages: 266-272
- DOI
  10.1016/j.radonc.2021.05.016
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K15616, KAKENHI-PROJECT-20H03684, KAKENHI-PROJECT-20K17207
[Journal Article] Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab2020
- Author(s)
  Yoko Tsukita, Eisaku Miyauchi, Masahide Fukudo, Takaaki Sasaki, Masakazu Ichinose
- Journal Title
  
  European journal of cancer
  
  Volume: 133 Pages: 22-24
- DOI
  10.1016/j.ejca.2020.04.008
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K17207
[Journal Article] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas2019
- Author(s)
  Tsukita Yoko、Fujino Naoya、Miyauchi Eisaku、Saito Ryoko、Fujishima Fumiyoshi、Itakura Koji、Kyogoku Yorihiko、Okutomo Koji、Yamada Mitsuhiro、Okazaki Tatsuma、Sugiura Hisatoshi、Inoue Akira、Okada Yoshinori、Ichinose Masakazu
- Journal Title
  
  Molecular Cancer
  
  Volume: 18 Issue: 1 Pages: 24-24
- DOI
  10.1186/s12943-019-0953-y
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K21266, KAKENHI-PROJECT-18K08134, KAKENHI-PROJECT-17H04149, KAKENHI-PROJECT-17H04180, KAKENHI-PROJECT-17K19785, KAKENHI-PROJECT-18K15942
[Journal Article] Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor52018
- Author(s)
  Yoko Tsukita, Tatsuma Okazaki, Satoru Ebihara, Riyo Komatsu, Mayumi Nihei, Makoto Kobayashi, Taizou Hirano, Hisatoshi Sugiura, Tsutomu Tamada, Nobuyuki Tanaka, Yasufumi Sato, Hideo Yagita, Masakazu Ichinose
- Journal Title
  
  OncoImmunology.
  
  Volume: 8(2) Issue: 2 Pages: 1543526-1543526
- DOI
  10.1080/2162402x.2018.1543526
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K08133, KAKENHI-PROJECT-18K08137, KAKENHI-PROJECT-16H05307, KAKENHI-PROJECT-19K21266
[Presentation] 非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索2023
- Author(s)
  木村望、突田容子、渋谷里紗、宮内栄作、他4名
- Organizer
  第63回日本呼吸器学会学術講演会
- Data Source
  KAKENHI-PROJECT-20K17207
[Presentation] First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057)2023
- Author(s)
  Mao Uematsu, Yoko Tsukita, Takehiro Tozuka, Kohei Kushiro, Shinobu Hosokawa, Toshiyuki Sumi, Osamu Honjo, Ou Yamaguchi, Tetsuhiko Asao, Jun Sugisaka, Go Saito, Jun Shiihara, Ryo Morita, Seigo Katakura, Takehiro Yasuda, Kakeru Hisakane, Eisaku Miyauchi, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina
- Organizer
  米国臨床腫瘍学会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K15180
[Presentation] A retrospective study of chemoradiotherapy with intensity-modulated radiotherapy for unresectable stage III NSCLC2021
- Author(s)
  Yoko Tsukita, Takaya Yamamoto, Eisaku Miyauchi, Hiroshi Mayahara, Akito Hata, Yuichiro Takeda, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura
- Organizer
  第18回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-20K17207
[Presentation] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas2018
- Author(s)
  Yoko Tsukita, Eisaku Miyauchi, Ryoko Saito, Tatsuma Okazaki, Akira Inoue, Yoshinori Okada, Masakazu Ichinose
- Organizer
  日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K21266
[Presentation] Axl Receptor Tyrosine Kinase Up-regulates Ligands for Programmed Cell Death 1 in Lung Adenocarcinoma2018
- Author(s)
  Yoko Tsukita, Naoya Fujino, Eisaku Miyauchi, Koji Itakura, Yorihiko Kyogoku, Mitsuhiro Yamada, Tatsuma Okazaki, Hisatoshi Sugiura, Masakazu Ichinose
- Organizer
  American Thoracic Society　Conferance
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-19K21266

1. 森本将裕

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
2. 岡崎達馬

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Tsukita Yoko 突田 容子

Research Projects

Research Products

Co-Researchers

進行期非小細胞肺癌の免疫併用療法におけるNK細胞の役割の解明Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Analysis of immune response induced by radiotherapy in non-small cell lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

The role of reactive sulfur species and cysteinyl-tRNA synthetase2 in lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70?years or older (‘MONEY’ trial)2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non?Small Cell Lung Cancer2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor52018

Author(s)

Journal Title

DOI

Data Source

[Presentation] 非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索2023

Author(s)

Organizer

Data Source

[Presentation] First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057)2023

Author(s)

Organizer

Data Source

[Presentation] A retrospective study of chemoradiotherapy with intensity-modulated radiotherapy for unresectable stage III NSCLC2021

Author(s)

Organizer

Data Source

[Presentation] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas2018

Author(s)

Organizer

Data Source

[Presentation] Axl Receptor Tyrosine Kinase Up-regulates Ligands for Programmed Cell Death 1 in Lung Adenocarcinoma2018

Author(s)

Organizer

Data Source

Tsukita Yoko 突田容子